Novo Nordisk Invests US$1.18 billion (DKK 8.5 billion) for New Production Facility in Denmark
Introduction:
Novo Nordisk plans to invest US$1.18 billion (DKK 8.5 billion) in opening a cutting-edge production facility in Odense, Denmark.
Features:
The new site, covering over 40,000 square meters, will include a state-of-the-art finished production unit and warehouse, designed with modularity and flexibility to support the production of various treatments for rare diseases, such as haemophilia, both now and in the future.
The facility with advanced technology and innovative equipment, aims to deliver the highest quality medicines while meeting the growing demand for life-changing therapies.
The project emphasises sustainability, including plans to protect the natural environment by planting over 4,000 trees and installing solar panels on the buildings to generate on-site electricity.
The site will also incorporate sustainable landscaping by reusing excess soil, wooden materials, and other resources to create lakes, forests, and community spaces accessible to the public.
Construction has already begun, with completion targeted for 2027, and the project is expected to create 400 permanent jobs once operational.
Specifications:
| Name : | Novo Nordisk |
| Type : | New Construction |
| Budget : | US$1.18 billion (DKK 8.5 billion) |
| Year : | 2027 |
